Education
About Us
Working with TipRanks
Follow Us
Autolus Therapeutics (AUTL)
:AUTL
Top Page
Autolus Therapeutics
(NASDAQ:AUTL)
43Neutral
Positive Factors
Regulatory Progress
MAA review is ongoing in the EU and U.K. with potential approvals expected.
Safety and Business Case
AUTL noted Aucatzyl's better safety and a better business case, allowing centers to treat more patients and hence greater profit.
Treatment Centers Expansion
33 US treatment centers now authorized for Aucatzyl, potentially able to reach ~60% of US patients.
Negative Factors
BNTX Option Not Exercised
BNTX did not exercise its option for AUTO1/22 in pediatric B-ALL.
Lack of Financial Guidance
Management did not provide guidance on sales or patient numbers due to difficulties in projecting these figures.
Autolus Therapeutics (AUTL) vs. S&P 500 (SPY)
Market Cap
$383.21M
Dividend YieldN/A
Average Volume (3M)1.61M
Price to Earnings (P/E)―
Beta (1Y)2.18
Revenue Growth496.00%
EPS Growth27.50%
CountryUS
Employees647
SectorHealthcare
Sector Strength66
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.87
Shares Outstanding266,128,900
10 Day Avg. Volume2,208,332
30 Day Avg. Volume1,605,929
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)44.29
Price to Cash Flow (P/CF)-1.50
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$8.67Price Target Upside502.08% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
Autolus Therapeutics Business Overview & Revenue Model
Company DescriptionAutolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1; AUTO6NG, a programmed T cell investigational therapy, which is in preclinical trail targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate that is in a Phase I clinical trial for multiple myeloma. It also focuses on developing AUTO5, a hematological product candidate, which is in preclinical development. The company was incorporated in 2014 and is headquartered in London, the United Kingdom.
How the Company Makes MoneyAutolus Therapeutics makes money primarily through the development and potential commercialization of its pipeline of programmed T cell therapies. The company's revenue streams include partnerships and collaborations with other pharmaceutical companies, which may involve upfront payments, milestone payments, and royalties on the sales of successfully developed products. Additionally, Autolus may generate income through licensing agreements, allowing other companies to utilize its proprietary technology for a fee. The company's earnings are significantly influenced by the progress and success of its clinical trials, regulatory approvals, and the competitive landscape within the biopharmaceutical industry.
Autolus Therapeutics Financial Statement Overview
Summary
Autolus Therapeutics shows strong revenue growth but faces persistent profitability and cash flow challenges. Despite a robust balance sheet with substantial cash reserves, operational losses and negative cash flows remain significant hurdles.Income Statement
Autolus Therapeutics has shown significant revenue growth in recent years, with a notable increase from $1.7M in 2023 to $10.1M in 2024. However, the company continues to report negative gross and net profit margins, indicating ongoing challenges in achieving profitability. The EBIT and EBITDA margins are also negative, reflecting substantial operational losses.25
Negative
Balance Sheet
The company's balance sheet highlights a strong equity position, with a substantial cash reserve relative to its liabilities. The debt-to-equity ratio is low at 0.12, suggesting limited leverage, but the company has consistently negative net income affecting ROE, which remains negative. The equity ratio is relatively stable, indicating a solid asset structure.40
Negative
Cash Flow
Autolus Therapeutics is facing challenges with negative free cash flow, which has worsened in recent periods. Although operating cash flow is negative, it is supported by financing activities, indicating reliance on external funding. The free cash flow to net income ratio is unfavorable, reflecting difficulties in converting income into cash.30
Negative
| Breakdown | ||||
| Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|
| Income Statement | Total Revenue | |||
| 10.12M | 1.70M | 6.19M | 2.33M | 242.00K |
| Gross Profit | ||||
| -1.27M | -4.87M | -131.03M | -126.32M | -134.65M |
| EBIT | ||||
| -241.43M | -195.03M | -163.78M | -164.21M | -168.15M |
| EBITDA | ||||
| -202.12M | -156.77M | -135.54M | -132.01M | -160.51M |
| Net Income Common Stockholders | ||||
| -220.66M | -208.38M | -148.84M | -142.10M | -142.09M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
| 588.02M | 239.57M | 382.44M | 310.34M | 153.30M |
| Total Assets | ||||
| 782.73M | 375.38M | 490.27M | 405.56M | 294.24M |
| Total Debt | ||||
| 52.63M | 52.97M | 24.26M | 21.00M | 54.16M |
| Net Debt | ||||
| -174.75M | -186.60M | -358.18M | -289.34M | -99.14M |
| Total Liabilities | ||||
| 355.40M | 263.91M | 191.60M | 92.24M | 84.20M |
| Stockholders Equity | ||||
| 427.32M | 111.47M | 298.67M | 313.32M | 210.03M |
| Cash Flow | Free Cash Flow | |||
| -206.27M | -156.57M | -123.15M | -126.72M | -132.44M |
| Operating Cash Flow | ||||
| -206.27M | -145.59M | -112.31M | -117.86M | -117.76M |
| Investing Cash Flow | ||||
| -394.55M | -10.99M | -10.84M | -8.86M | -14.68M |
| Financing Cash Flow | ||||
| 589.55M | -883.00K | 223.61M | 284.06M | 74.42M |
Autolus Therapeutics Technical Analysis
Negative
1.44
Price Trends
1.72
Negative
2.11
Negative
3.03
Negative
Market Momentum
-0.11
Negative
45.90
Neutral
75.01
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AUTL, the sentiment is Negative. The current price of 1.44 is below the 20-day moving average (MA) of 1.44, below the 50-day MA of 1.72, and below the 200-day MA of 3.03, indicating a bearish trend. The MACD of -0.11 indicates Negative momentum. The RSI at 45.90 is Neutral, neither overbought nor oversold. The STOCH value of 75.01 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AUTL.
Autolus Therapeutics Risk Analysis
Autolus Therapeutics disclosed 86 risk factors in its most recent earnings report. Autolus Therapeutics reported the most risks in the “Tech & Innovation” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Autolus Therapeutics Peers Comparison
Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $5.19B | 3.13 | -40.94% | 2.95% | 17.94% | 2.00% | |
51 Neutral | $393.52M | ― | -58.04% | ― | -20.71% | 22.25% | |
44 Neutral | $350.41M | ― | -59.86% | ― | -95.31% | 18.58% | |
44 Neutral | $370.44M | ― | -24.68% | ― | ― | ― | |
44 Neutral | $387.48M | ― | -87.54% | ― | ― | -4.14% | |
43 Neutral | $383.21M | ― | -81.91% | ― | 496.00% | 27.50% | |
40 Underperform | $411.22M | ― | -28.99% | ― | ― | 74.59% |
* Healthcare Sector Average
Performance Comparison
AUTL
Autolus Therapeutics
1.44
-3.12
-68.42%
ALT
Altimmune
4.79
-2.68
-35.88%
CELC
Celcuity
10.45
-7.09
-40.42%
TRML
Tourmaline Bio
16.76
1.26
8.13%
ABSI
AbSci
3.07
-1.44
-31.93%
RAPP
Rapport Therapeutics, Inc.
10.38
-15.81
-60.37%
Autolus Therapeutics Earnings Call Summary
Earnings Call Date: Mar 20, 2025 | % Change Since: -25.77% | Next Earnings Date: May 1, 2025
Earnings Call Sentiment Positive
The earnings call reflects a generally positive sentiment, highlighting the successful U.S. launch of AUCATZYL, strong financial backing, and promising clinical data. However, financial challenges remain with increased operating and net losses, as well as high R&D expenditures.Highlights
Successful Commercial Launch of AUCATZYL
The commercial launch of AUCATZYL in the U.S. is progressing well, with 33 centers authorized as of March 19, covering approximately 60% of the target patient population. The company expects to have 60 centers by year-end, potentially covering the majority of U.S. patients.
U.S. Approval and Positive Label for obe-cel
Obe-cel was approved in the U.S. on November 8, slightly ahead of schedule, with a favorable label for relapsed refractory ALL in adult patients and without a REMS program, indicating a strong foundation for commercial use.
Strong Financial Position
Added $600 million to the balance sheet through collaboration with BioNTech and public financing, resulting in a cash position of $588 million at year-end 2024, compared to $239 million at the end of 2023.
Positive Clinical Data
Published clinical results in the New England Journal of Medicine, showing high clinical activity and an attractive safety profile of obe-cel, with low levels of high-grade CRS and ICANS.
Strategic Milestone Payments
Received $30 million milestone payment from Blackstone following FDA approval, demonstrating financial support and collaboration success.
Lowlights
Increased Operating Loss
Loss from operations increased to $241.4 million for 2024, up from $179.7 million in 2023, primarily due to increased R&D and SG&A expenses.
Sustained Net Loss
Reported a net loss of $220.7 million for 2024, up from $208.4 million in 2023, indicating ongoing financial challenges despite revenue potential.
High Manufacturing and R&D Costs
Research and development expenses increased to $138.4 million in 2024 from $130.5 million in 2023, driven by higher employee costs and manufacturing expenses for obe-cel.
Company Guidance
During the Autolus Therapeutics call discussing the full year 2024 financial results and business updates, several key metrics were highlighted. The company reported cash, cash equivalents, and marketable securities totaling $588 million at the end of 2024, which was an increase from $239 million at the end of 2023, primarily due to a $600 million collaboration with BioNTech. The loss from operations for 2024 was $241.4 million, compared to $179.7 million in 2023. The commercial launch of AUCATZYL in the U.S. was a primary focus, with 33 centers authorized as of March 19, 2025, expected to reach approximately 60% of the target patient population. Autolus aims to onboard about 60 centers by year-end, covering the majority of U.S. patients. The company received a $30 million milestone payment from Blackstone following FDA approval of AUCATZYL, and ongoing regulatory processes in the UK and EU are expected to yield decisions in the second half of 2025. The call also addressed the upcoming R&D event on April 23, 2025, in New York, where further details on expanding the utility of obe-cel and other product candidates will be shared.Autolus Therapeutics Corporate Events
Executive/Board Changes
Autolus Therapeutics Announces Leadership Transition in Finance
Neutral
Apr 3, 2025
On February 24, 2025, Autolus Therapeutics announced the resignation of Andrew Mercieca, Vice President of Finance and principal accounting officer, effective August 2025. His departure is amicable and not due to any disagreements with the company. On April 3, 2025, the Board appointed Rob Dolski, the current CFO, as the new principal accounting officer, consolidating his roles without additional compensation, indicating a seamless transition in leadership.
Product-Related AnnouncementsBusiness Operations and StrategyFinancial Disclosures
Autolus Therapeutics Launches AUCATZYL® in U.S. Market
Positive
Mar 20, 2025
Autolus Therapeutics reported its financial results for the year ended December 31, 2024, highlighting significant achievements such as the FDA approval and U.S. commercial launch of AUCATZYL® for adult B-cell acute lymphoblastic leukemia. The company has authorized 33 treatment centers as of March 19, 2025, and aims to expand further in the U.S. and new markets while advancing its clinical pipeline. Autolus also anticipates regulatory decisions in the EU and UK for obe-cel and is progressing with trials in autoimmune diseases. Financially, the company ended 2024 with increased cash reserves, driven by a strategic collaboration with BioNTech, despite reporting a net loss of $220.7 million.
Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.